癌症研究
下调和上调
免疫疗法
单核细胞
肝细胞癌
自分泌信号
免疫系统
细胞毒性T细胞
癌症免疫疗法
CD86
生物
免疫学
医学
内科学
体外
T细胞
受体
基因
生物化学
作者
Yongchun Wang,Zhenjun Ma,Weibai Chen,Junfeng Wang,Zhijie Huang,Xing-Juan Yu,Yaojun Zhang,Limin Zheng,Jing Xu
标识
DOI:10.1016/j.canlet.2024.216638
摘要
Recent studies have suggested that therapeutic upregulation of CCAAT/enhancer binding protein α (C/EBPα) prevents hepatocellular carcinoma (HCC) progression. However, the mechanisms underlying this outcome are not fully understood. In this study, we investigated the expression and functional roles of C/EBPα in human HCC, with a focus on monocytes/macrophages (Mφs). Paraffin-embedded tissues were used to visualize C/EBPα expression and analyze the prognostic value of C/EBPα+ monocytes/Mφs in HCC patients. The underlying regulatory mechanisms were examined using human monocyte-derived Mφs. The results showed that the expression of C/EBPα on monocytes/Mφs was significantly decreased in intra-tumor tissues compared to the corresponding peri-tumor tissues. C/EBPα+ monocytes/Mφs displayed well-differentiation and antitumor capacities, and the accumulation of these cells in tissue was associated with antitumor immune responses and predicted longer overall survival (OS) of HCC patients. Mechanistic studies demonstrated that C/EBPα was required for Mφ maturation and HLA-DR, CD169 and CD86 expression, which initiates antitumor cytotoxic T-cell responses; however, these effects were inhibited by monocyte autocrine IL-6- and IL-1β-induced suppression of mTOR1 signaling. Reprogramming Mφs via the upregulation of C/EBPα may provide a novel strategy for cancer immunotherapy in patients with HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI